On August 12, 2021, the FDA updated the Emergency Use Authorization (EUA) for the COVID-19 vaccines from Moderna and Pfizer/BioNTech to permit a third booster dose for individuals with immunocompromising conditions, such as those who have received an organ transplant or an equivalent immunocompromising condition. Immunocompromised patients who require the third booster dose may receive it 28 days after their second shot. The EUA is amended for Moderna’s vaccine in individuals 18 years of age and older and Pfizer/BioNTechs’s vaccine is amended for individuals 12 years of age and older. The FDA made their decision based on information that a third dose may be moderately effective at increasing antibody titers for immunocompromised individuals since they have a reduced ability to fight off vulnerable infections. The U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) is meeting today, August 13, 2021, to make a recommendation on the FDA decision. For information on the Pfizer-BioNTech COVID-19 vaccine, see here. For information on the Moderna COVID-19 vaccine, see here.